Celontin in patients with refractory epilepsy

Publisher Website
Google Scholar
Abstract
Of 54 patients receiving Celontin (N-methyl-a, a-methylphenylsuccinimide) long enough for adequate evaluation, 6 patients achieved complete seizure control, 6 were distinctly improved, and 5 patients experienced an increase in seizure frequency on the drug. The remainder noted little or no improvement. Age, clinical seizure type, and eeg pattern bore little relation to the level of improvement. Principal side effects were sedation and ataxia.

This publication has 1 reference indexed in Scilit: